Research & Economic Development

Office of the Vice Chancellor

Quick Links

Ensure the Safe Use of Biohazardous Substances

IBC Community Membership

University of Missouri-Kansas City Research Protections is seeking the help of community members in our mission to ensure institutional oversight of recombinant DNA research.

We are looking for community members to serve on UMKC's Institutional Biosafety Committee (IBC). By federal regulations, the IBC must have 2 members who are not affiliated with the University.

If you have questions or are interested in become a member, please contact Chris Winders, Director of Research Compliance, at or Lori Reierson, IBC coordinator at or 816-235-5929.

The Institutional Biosafety Committee, or IBC, ensures the safe use of biohazardous materials in research. The goal: eliminate or reduce the potential exposure of personnel or the environment. “Biohazardous materials” are defined as materials of biological origin that have the capacity to produce deleterious effects on humans or animals. These include:

  • recombinant DNA molecules
  • microorganisms classified in various Risk Groups (RG-1, RG-2, RG-3, or RG-4) and their biological products
  • specimens known to (or reasonably expected to) contain human pathogens
  • hazardous microorganisms
  • combinations of or waste derived from these

This responsibility is described in the IBC Policy Procedure Manual 5 5 2015, including IBC's Standard Operating Procedures. The UMKC IBC is the IBC-of-record for research at affiliated Kansas City institutions, including Children's Mercy Hospital, Saint Luke's Hospital, and Truman Medical Center. The IBC and its Biosafety Officers (BSOs) are responsible to evaluate and monitor research and teaching at UMKC and the affiliated institutions for biological safety considerations.

Essential Information

UMKC IBC Human Cell Line policy

Changes to Federal Oversight of Human Gene Transfer

August 2018: Requirement Removed

The NIH Office of Science Policy will no longer require review by its Recombinant DNA Advisory Committee (RAC) of proposed HGT protocols or reports.

For details, see the NIH Director's Statement

Contact the IBC

IBC Compliance Office
816 235-5929

IBC Chair
Dr. Sullivan Read
816 235-2583

Biosafety Officer, UMKC
Jennifer Smith

Biosafety Officer, Children's Mercy

Paul Ramlow
816 983-6944 (x56944)

Biosafety Officer, St. Luke's
Suparna Nanua
816 932-3981


Recent NewsView all